HCA Healthcare (HCA)
(Delayed Data from NYSE)
$404.66 USD
+1.14 (0.28%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $404.42 -0.24 (-0.06%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$404.66 USD
+1.14 (0.28%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $404.42 -0.24 (-0.06%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Zacks News
Q2 Earnings Season Scorecard and Analyst Reports for Netflix, Wells Fargo & Comcast
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Netflix (NFLX), Wells Fargo (WFC) and Comcast (CMCSA) and others.
Community Health (CYH) Q2 Earnings Miss on Lower Patient Days
by Zacks Equity Research
Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Here's Why HCA Healthcare (HCA) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Tenet Healthcare Corporation (THC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bet on These 5 Attractive Relative Price Strength Plays
by Nilanjan Choudhury
STX, RGA, HCA, IP and OSW are five stocks with explosive relative price strength.
Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.
2 Standout Stocks to Buy After Beating Earnings Expectations
by Shaun Pruitt
Now looks like a promising time to invest in the increased profitability of HCA Healthcare (HCA) and Spotify Technology (SPOT) after beating Q2 earnings expectations on Tuesday.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
by Zacks Equity Research
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HCA Healthcare (HCA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 10.66% and 2.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Buying Tenet (THC) Pre-Q2 Earnings: A Prescription for Profits?
by Kaibalya Pravo Dey
Tenet Healthcare's (THC) second-quarter earnings are likely to have benefited from higher admissions, average length of stay and patient days.
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
What's in Store for Texas Instruments (TXN) in Q2 Earnings?
by Zacks Equity Research
Texas Instruments' (TXN) second-quarter 2024 results are likely to reflect the adverse impacts of a weak demand environment and increasing manufacturing costs.
4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.
Tenet Healthcare (THC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.